You are here

Legend Biotech

J&J sees trial data supporting earlier CAR-T use in multiple myeloma

J&J sees trial data supporting earlier CAR-T use in multiple myeloma

BioPharma Dive

Multiple Myeloma

Flag link:

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

Fierce Pharma

Bristol Myers Squibb

Multiple Myeloma

Flag link:

Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls

Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls

Fierce Pharma

Flag link:

J&J, Legend’s cancer cell therapy has early success in key clinical trial

J&J, Legend’s cancer cell therapy has early success in key clinical trial

BioPharma Dive

Multiple Myeloma

clinical trials

Flag link:

Sales of J&J, Legend cell therapy plateau amid production challenges

Sales of J&J, Legend cell therapy plateau amid production challenges

BioPharma Dive

Multiple Myeloma

Flag link:

Gilead lands new cell therapy for Kite in $225M Arcellx deal

Gilead lands new cell therapy for Kite in $225M Arcellx deal

Fierce Biotech

Gilead Sciences

clinical trials

Multiple Myeloma

Flag link:

FDA approves Legend Biotech’s IND application for lung cancer therapy trial

FDA approves Legend Biotech’s IND application for lung cancer therapy trial

Clinical Trials Arena

small cell lung cancer

Flag link:

J&J partner Legend Biotech looks to raise $250M amid Carvykti rollout, global expansion

J&J partner Legend Biotech looks to raise $250M amid Carvykti rollout, global expansion

Fierce Pharma

Flag link:

Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted

Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted

Fierce Biotech

clinical trials

Flag link:

ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population

ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population

Fierce Pharma

Multiple Myeloma

Flag link:

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

BioSpace

Flag link:

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

Motley Fool

TCR immunotherapy

Flag link:

J&J, Legend cell therapy approved by FDA for multiple myeloma

J&J, Legend cell therapy approved by FDA for multiple myeloma

BioPharma Dive

Multiple Myeloma

Flag link:

Legend's early-stage CAR-T on FDA hold after single patient dosed

Legend's early-stage CAR-T on FDA hold after single patient dosed

Fierce Biotech

clinical trials

Flag link:

Go or no go? PDUFA resolutions eyed for J&J and Amryt

Go or no go? PDUFA resolutions eyed for J&J and Amryt

EP Vantage

ciltacabtagene autoleucel

Flag link:

JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch

JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch

Fierce Pharma

Flag link:

Why Legend Biotech Shares Plummeted 17.6% Wednesday

Why Legend Biotech Shares Plummeted 17.6% Wednesday

Motley Fool

Flag link:

FDA pushes back decision on J&J, Legend's BCMA CAR-T

FDA pushes back decision on J&J, Legend's BCMA CAR-T

Endpoints

Flag link:

Will This 2020 Biotech IPO Crush the Market This Year?

Will This 2020 Biotech IPO Crush the Market This Year?

Motley Fool

Multiple Myeloma

Flag link:

Legend Biotech and Janssen establish Belgium cell therapy site

Legend Biotech and Janssen establish Belgium cell therapy site

Biopharma Reporter

Flag link:

Pages